Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press63510.17650/1994-4098-2019-15-1-67-72GYNECOLOGY. REVIEWSГИНЕКОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИPrognostic value of microcirculatory changes and alterations in the cellular microenvironment in patients with glandular hyperplasia of the endometrium and endometrial cancer (literature review)Прогностическое значение изменений микроциркуляторного русла и клеточного микроокружения при железистой гиперплазии эндометрия и раке эндометрия (обзор литературы)https://orcid.org/0000-0002-8080-904XKornevaYu. S.КорневаЮ. С.
Russian Federation

28 Krupskoy St., Smolensk 214019, 

27 Prospekt Gagarina, Smolensk 214018

Юлия Сергеевна Корнева

214019 Смоленск, ул. Крупской, 28, 

214020 Смоленск, проспект Гагарина, 27

ksu1546@yandex.ruhttps://orcid.org/0000-0002-0590-1399UkrainetsR. V.УкраинецР. В.
Russian Federation

27 Prospekt Gagarina, Smolensk 214018

214020 Смоленск, проспект Гагарина, 27

DorosevichA. E.ДоросевичА. Е.
Russian Federation

28 Krupskoy St., Smolensk 214019, 

27 Prospekt Gagarina, Smolensk 214018

214019 Смоленск, ул. Крупской, 28, 

214020 Смоленск, проспект Гагарина, 27

Smolensk State Medical University, Ministry of Health of RussiaФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава РоссииSmolensk Regional Institute of PathologyОГБУЗ «Смоленcкий областной институт патологии»0107201915167720107201901072019https://ojrs.abvpress.ru/ojrs/article/view/635

This article summarizes the results of the most recent studies exploring changes in the stromal component of the endometrial tissue during malignant transformation in patients with precancerous conditions, particularly transformation of glandular hyperplasia of the endometrium into endometrioid adenocarcinoma. We cover the most important issues related to microcirculatory remodeling and changes in the cellular microenvironment of the stroma in terms of the effects exerted by biologically active molecules produced by different cell populations. We analyzed specific changes occurring in the stromal components in various types of glandular hyperplasia of the endometrium and changes during endometrioid adenocarcinoma progression. We focus on the prognostic and diagnostic values of these morphological changes, considering the results of the latest molecular studies, which can be later used for personalization of patient prognosis.

В статье обобщены результаты последних исследований, посвященных изучению изменений стромального компонента эндометрия при злокачественной трансформации предраковых состояний, а именно железистой гиперплазии эндометрия в эндометриоидную аденокарциному. Особое внимание уделяется ремоделированию микроциркуляторного русла, а также изменению клеточного микроокружения в строме с точки зрения эффектов биологически активных молекул, выделяемых различными клеточными популяциями. Динамика изменения компонентов стромы оценивается для различных видов железистой гиперплазии эндометрия, а также учитывая изменения, возникающие при прогрессии эндометриоидной аденокарциномы. Акцент делается на прогностическое и диагностическое значение данных морфологических изменений с учетом современных молекулярно-генетических исследований, что может стать теоретической основой для персонализации прогноза пациенток.

glandular hyperplasia of the endometriumendometrioid adenocarcinomamicrocirculatory bedmacrophagesfibroblastslymphocytesжелезистая гиперплазия эндометрияэндометриоидная аденокарциномамикроциркуляторное русломакрофагифибробластылимфоцитыHanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74. DOI: 10.1016/j.cell.2011.02.013.Osinskiy S.P. Microenvironment of tumorous cells and tumor progression. Factors of stromal microenviroment. Zdorov’e Ukraini 2013;3(28): 36–9. (In Russ.).Осинский С.П. Микроокружение опухолевых клеток и опухолевая прогрессия. Факторы стромального микроокружения. Здоровье Украины 2013;3(28):36–9.Bantysh B.B., Paukov V.S., Kogan E.A. Immunomorphologic features of epithelial-stromal relationships at hyperplasia and endometrial carcinoma. Arkhive Patologii 2012;(3):22–5. (In Russ.).Бантыш Б.Б., Пауков В.С., Коган Е.А. Иммуноморфометрические особенности эпителиально-стромальных взаимоотношений при гиперплазии и раке эндометрия. Архив патологии 2012;(3): 22–5.Czekierdowski A., Czekierdowska S., Czuba B. et al. Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol 2008;59(4):45–51.Horrée N., van Diest P.J., van der Groep P. et al. Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 2007;29(3):219–27.Abulafia O., Triest W.E., Sherer D.M. et al. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995;86(4):479–85.Erdem O., Erdem M., Erdem A. et al. Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Cancer 2007;17(6):1327–32.Saad R.S., Jasnosz K.M., Tung M.Y., Silverman J.F. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 2003;22(3):248–53. DOI: 10.1097/01.PGP.0000070852.25718.37.Dai H., Zhao S., Xu L. et al. Expression of Efp, VEGF and bFGF in normal, hyperplastic and malignant endometrial tissue. Oncol Rep 2010;23(3):795–9.Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res 2001;21(6): 4383–8.Yokoyama Y., Charnock-Jones D.S., Licence D. et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 2003;9(4):1361–9.Fujiwaki R., Iida K., Kanasaki H. et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002;33(2):213–9.Boruban M.C., Altundag K., Kilic G.S., Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 2008;17(2):133–8. DOI: 10.1097/CEJ.0b013e32811080ce.Feng Z., Gan H., Cai Z. et al. Aberrant expression of hypoxia-inducible factor 1α, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma. Jpn J Clin Oncol 2013;43(4):396–403. DOI: 10.1093/jjco/hys237.Yunokawa M., Tanimoto K., Nakamura H. et al. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas. Oncol Rep 2007;17(4):871–8.Ashton-Sager A., Paulino A.F., Afify A.M. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol 2006;14(2):187–92. DOI: 10.1097/01.pai.0000162003.43334.c7.Lindberg M.E., Stodden G.R., King M.L. et al. Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus. Biol Reprod 2013;89(1):8. DOI: 10.1095/biolreprod.113.109462.Hamid A.A., Mandai M., Fujita J. et al. Expression of cold-inducible RNA-binding protein in the normal endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Pathol 2003;22(3):240–7. DOI: 10.1097/01.PGP.0000070851.25718.EC.Nakamura K., Hongo A., Kodama J. et al. Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Res 2009;29(5):1685–90.Nakamura K., Kodama J., Hongo A., Hiramatsu Y. Role of emmprin in endometrial cancer. BMC Cancer 2012;12:191. DOI: 10.1186/1471-2407-12-191.Krikun G., Mor G., Huang J. et al. Metalloproteinase expression by control and telomerase immortalized human endometrial endothelial cells. Histol Histopathol 2005;20(3):719–24. DOI: 10.14670/HH20.719.Silver S.A., Sherman M.E. Morphologic and immunophenotypic characterization of foam cells in endometrial lesions. Int J Gynecol Pathol 1998;17(2):140–5.Iavazzo C., Kalmantis K., Ntziora F. et al. Detection of large histiocytes in pap smears: role in the prediction of endometrial pathology? Bratisl Lek Listy 2008;109(11):497–8.Nguyen T.N., Bourdeau J.L., Ferenczy A., Franco E.L. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagn Cytopathol 1998;19(2):89–93.Nassar A., Fleisher S.R., Nasuti J.F. Value of histiocyte detection in Pap smears for predicting endometrial pathology. An institutional experience. Acta Cytol 2003;47(5):762–7. DOI: 10.1159/000326602.Ashkenazy M., Lancet M., Borenstein R., Czernobilsky B. Endometrial foam cells. Non-estrogenic and estrogenic. Acta Obstet Gynecol Scand 1983;62(3):193–7.Kelly M.G., Francisco A.M., Cimic A. et al. Type 2 Endometrial cancer is associated with a high density of tumor-associated macrophages in the stromal compartment. Reprod Sci 2015;22(8):948–53. DOI: 10.1177/1933719115570912.Hu H.L., Bai H.S., Pan H.X. Correlation between TAMs and proliferation and invasion of type I endometrial carcinoma. Asian Pac J Trop Med 2015;8(8):643–50. DOI: 10.1016/j.apjtm.2015.07.009.Jiang X.F., Tang Q.L., Li H.G. et al. Tumorassociated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res 2013;39(4):855–63. DOI: 10.1111/j.1447-0756.2012.02036.x.Dun E.C., Hanley K., Wieser F. et al. Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas Int J Gynecol Pathol 2013;32(6):576–84. DOI: 10.1097/PGP.0b013e318284e198.Jiang X.F., Tang Q.L., Shen X.M. et al. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma. Pathol Res Pract 2012;208(12):730–5. DOI: 10.1016/j.prp.2012.09.011.Soeda S., Nakamura N., Ozeki T. et al. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 2008;109(1):122–8. DOI: 10.1016/j.ygyno.2007.12.033.Xiao W., Jin O., Han S. et al. Correlations of leukemia inhibitory factor and macrophage migration inhibitory factor with endometrial carcinoma. Eur J Gynaecol Oncol 2015;36(2):146–9.Xiao W., Dong X., Zhao H. et al. Expression of MIF and c-erbB-2 in endometrial cancer. Mol Med Rep 2016;13(5): 3828–34. DOI: 10.3892/mmr.2016.4992.Ribatti D., Finato N., Crivellato E. et al. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol 2005;193(6):1961–5. DOI: 10.1016/j.ajog.2005.04.055.D’Souza O.A., Rameshkumar K., Nirmala V. Mast cells and macrophages in endometrial lesions. Indian J Pathol Microbiol 1994;37(4):367–73.Erdem O., Erdem M., Erdem A. et al. Expression of vascular endothelial growth factor and assessment of micro vascular density with CD 34 and endog lin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Cancer 2007;17(6):1327–32.Subramaniam K.S., Tham S.T., Mohamed Z. et al. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS One 2013;8(7):e68923. DOI: 10.1371/journal.pone.0068923.Subramaniam K.S., Omar I.S., Kwong S.C. et al. Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway. Am J Cancer Res 2016;6(2): 200–13.Gold L.I., Saxena B., Mittal K.R. et al. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 1994;54(9):2347–58.Wang Y.K., Cui N., Li J., Luo B. Expression of pituitary tumor-transforming gene in endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi 2004;39(8):538–42.Peng W.X., Kudo M., Fujii T. et al. Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation. Int J Clin Exp Pathol 2014;7(3):1069–76.Hachisuga T., Fukuda K., Nakamura S. et al. Local immune response in endometrial carcinomas. Br J Obstet Gynaecol 1997;104(1):110–4.Pascual-García M., Bértolo C., Nieto J.C. et al. CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas. Hum Pathol 2016;56:180–8. DOI: 10.1016/j.humpath.2016.05.025.Levakov S.A., Zaĭrat'iants O.V., Sidorova I.S. et al. Detection rates of various serotypes of human papilloma virus in atypical glandular hyperplasia and adenocarcinoma of the endometrium and their immunomorphological features in virus-positive cases. Arkhive Patologii 2007;69(2):6–9. (In Russ.).Леваков С.А., Зайратьянц О.В., Сидорова И.С. и др. Частота выявления разных серотипов вируса папилломы человека при атипической железистой гиперплазии и аденокарциноме эндометрия и их иммуноморфологические особенности в вируспозитивных наблюдениях. Архив патологии 2007;69(2):6–9.Zbroch T., Knapp P., Knapp P. Human papilloma virus (HPV) infection in the pathology of the endometrium. Role of immunological activation in antiviral and antineoplastic defense. Med Wieku Rozwoj 2002;6(1):43–55.Polishchuk L.Z., Nesina I.P. Structural chromosome aberrations in the peripheral blood lymphocytes in patients with precancer and endometrial cancer. Tsitol Genet 1995;29(3):17–24.Workel H.H., Komdeur F.L., Wouters M.C. et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur J Cancer 2016;60:1– 11. DOI: 10.1016/j.ejca.2016.02.026.Čermáková P., Melichar B., Tomšová M. et al. Prognostic significance of CD3+ tumorinfiltrating lymphocytes in patients with endometrial carcinoma. Anticancer Res 2014;34(10):5555–61.Allhorn S., Böing C., Koch A.A. et al. TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol 2008;6:40. DOI: 10.1186/1477-7827-6-40.Witkiewicz A.K., McConnell T., Potoczek M. et al. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Hum Pathol 2010;41(1):26–32. DOI: 10.1016/j.humpath.2009.06.012.Brunner A., Hinterholzer S., Riss P. et al. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 2012;124(1): 105–11. DOI: 10.1016/j.ygyno.2011.09.012.Miyatake T., Tringler B., Liu W. et al. B7H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 2007;106(1):119–27. DOI: 10.1016/j.ygyno.2007.03.039.